A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease
Phase 3
Active, not recruiting
- Conditions
- Chronic Graft-versus-host-disease
- Interventions
- First Posted Date
- 2024-02-16
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Incyte Biosciences Japan GK
- Target Recruit Count
- 21
- Registration Number
- NCT06263478
- Locations
- 🇯🇵
Okayama University Hospital, Okayama, Japan
🇯🇵Osaka Prefectural Hospital Organization Osaka International Cancer Institute, Osaka, Japan
🇯🇵Fujita Health University Hospital, Aichi, Japan
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INCB054707
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2022-09-16
- Lead Sponsor
- Incyte Biosciences Japan GK
- Target Recruit Count
- 30
- Registration Number
- NCT05068466
- Locations
- 🇯🇵
Souseikai Fukuoka Mirai Hospital, Fukuoka, Japan
To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2022-11-15
- Lead Sponsor
- Incyte Biosciences Japan GK
- Target Recruit Count
- 3
- Registration Number
- NCT04674748
- Locations
- 🇯🇵
National Cancer Center Hospital - East, Chiba, Japan
🇯🇵National Cancer Center Hospital, Tokyo, Japan
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)
Phase 1
Recruiting
- Conditions
- Non Hodgkins LymphomaDiffuse Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Incyte Biosciences Japan GK
- Target Recruit Count
- 65
- Registration Number
- NCT04661007
- Locations
- 🇯🇵
Aichi Cancer Center Hospital, Aichi, Japan
🇯🇵Chiba Cancer Center, Chiba, Japan
🇯🇵National Cancer Center Hospital East, Chiba, Japan
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
- First Posted Date
- 2020-06-17
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Incyte Biosciences Japan GK
- Target Recruit Count
- 42
- Registration Number
- NCT04434937
- Locations
- 🇯🇵
Hyogo College of Medicine Hospital, Hyogo, Japan
🇯🇵Shizuoka Cancer Center, Shizuoka, Japan
🇯🇵Nho Shikoku Cancer Center, Matsuyama, Japan
A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Solid TumorsMetastatic Solid Tumors
- Interventions
- First Posted Date
- 2019-04-10
- Last Posted Date
- 2022-02-25
- Lead Sponsor
- Incyte Biosciences Japan GK
- Target Recruit Count
- 18
- Registration Number
- NCT03910530
- Locations
- 🇯🇵
National Cancer Center Hospital East, Kashiwa, Japan
🇯🇵National Cancer Center Hospital, Chuo Ku, Japan
© Copyright 2025. All Rights Reserved by MedPath